topiramat "hexal" 50 mg filmovertrukne tabletter
hexal a/s - topiramat - filmovertrukne tabletter - 50 mg
topiramat "orion" 100 mg filmovertrukne tabletter
orion corporation - topiramat - filmovertrukne tabletter - 100 mg
topiramat "orion" 200 mg filmovertrukne tabletter
orion corporation - topiramat - filmovertrukne tabletter - 200 mg
topiramat "orion" 50 mg filmovertrukne tabletter
orion corporation - topiramat - filmovertrukne tabletter - 50 mg
topiratore 100 mg filmovertrukne tabletter
stada arzneimittel ag - topiramat - filmovertrukne tabletter - 100 mg
topiratore 200 mg filmovertrukne tabletter
stada arzneimittel ag - topiramat - filmovertrukne tabletter - 200 mg
topiratore 25 mg filmovertrukne tabletter
stada arzneimittel ag - topiramat - filmovertrukne tabletter - 25 mg
topiratore 50 mg filmovertrukne tabletter
stada arzneimittel ag - topiramat - filmovertrukne tabletter - 50 mg
insulin lispro sanofi
sanofi winthrop industrie - insulin lispro - diabetes mellitus - narkotika anvendt i diabetes - til behandling af voksne og børn med diabetes mellitus, der kræver insulin til opretholdelse af normal glukose homøostase. insulin lispro sanofi er også indiceret til den indledende stabilisering af diabetes mellitus.
sitagliptin accord
accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.